Animal Model Core

Information

  • Research Project
  • 10237855
  • ApplicationId
    10237855
  • Core Project Number
    U19AI062629
  • Full Project Number
    5U19AI062629-18
  • Serial Number
    062629
  • FOA Number
    RFA-AI-17-040
  • Sub Project Id
    7836
  • Project Start Date
    9/15/2004 - 20 years ago
  • Project End Date
    8/31/2024 - 2 months ago
  • Program Officer Name
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    18
  • Suffix
  • Award Notice Date
    8/13/2021 - 3 years ago

Animal Model Core

Project Summary Our U19 program is focused on the investigation of the pathophysiology of B. anthracis infection and sepsis and potential novel therapies. The Animal Core will serve as an integral component of the U19 program, providing support to all three projects using a clinically relevant animal model of sepsis. The investigators will have a unique opportunity to answer critical questions by combining a genetically diverse, clinically relevant animal model, which has a proven history of mimicking human responses to sepsis with novel technologies being developed within our program. The Animal Core combines a unique set of facilities, management and technical expertise needed to achieve the Specific Aims of this program, as well as expert veterinary care, specialized reagent tools and strong expertise in advanced biochemical and microscopical analysis of tissue samples. The personnel involved in the Core have more than three decades of experience in infectious disease modeling in non-human primates. Optimal utilization of clinically relevant animal models for research on bioterrorism related pathogens such as B. anthracis requires a facility where animals are housed in appropriate biocontainment, research personnel are experienced in the methodologies required for infectious disease research, and development of novel therapeutics is required. Our Animal Core will use state-of-the-art facilities to develop animal models for studying disease pathogenesis and testing the efficacy and safety of novel therapeutics. Our facilities fully support biohazard research at ABSL-2 and meet all the NIH/CDC guidelines. Hence, this Core is a critical component in support of the proposals aimed at developing innovative therapeutics against B. anthracis, which we believe will be relevant to other Gram-positive pathogens.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U19
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    431314
  • Indirect Cost Amount
    160429
  • Total Cost
  • Sub Project Total Cost
    591743
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIAID:591743\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OKLAHOMA MEDICAL RESEARCH FOUNDATION
  • Organization Department
  • Organization DUNS
    077333797
  • Organization City
    OKLAHOMA CITY
  • Organization State
    OK
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    731045005
  • Organization District
    UNITED STATES